AI Article Synopsis

  • Inflammatory bowel disease (IBD) involves chronic inflammation of the gastrointestinal tract, and its incidence has increased significantly in recent years.
  • This study reviews literature on the use of fecal calprotectin for diagnosing IBD, assessing disease severity, predicting relapses, and monitoring remission.
  • It highlights that elevated fecal calprotectin levels correlate with relapses in IBD, suggesting it can be a valuable diagnostic tool alongside traditional methods like endoscopy and histopathological tests.

Article Abstract

Inflammatory bowel disease (IBD) is a group of diseases characterized by chronic and recurrent inflammation of the gastrointestinal tract. The incidence of IBD has increased significantly in past decades. The aim of this study is to review the literature on the possibility of using fecal calprotectin in the diagnosis of inflammatory bowel disease, the assessment of the severity of the disease, the prediction of a relapse and the monitoring of remission. The literature review was conducted using the PubMed and Google Scholar databases. Most of the publications included in the study are from 2013 or later. Laboratory, imaging, endoscopic and histopathological tests are used in the diagnosis of IBD. In order to confirm the diagnosis, an endoscopic examination with the collection and evaluation of histopathological specimens is required. Laboratory tests useful in the diagnosis of non-specific inflammations include non-specific tests such as the white blood cells count, ESR and CRP. Faecal calprotectin is a protein complex produced by neutrophils in the inflamed gut. The studies included in this review have shown the presence of increased levels of fecal calprotectin in patients with relapses in the course of inflammatory bowel disease. Accordingly, determination of this marker may be useful in the diagnosis of chronic abdominal pain and as screening prior to colonoscopy.

Download full-text PDF

Source

Publication Analysis

Top Keywords

inflammatory bowel
16
bowel disease
12
fecal calprotectin
8
tests diagnosis
8
diagnosis
5
[fecal calprotectin
4
calprotectin diagnostic
4
diagnostic marker
4
inflammatory
4
marker inflammatory
4

Similar Publications

Arginase (ARG) is a binuclear manganese-containing metalloenzyme that can convert L-arginine to L-ornithine and urea and plays a key role in the urea cycle. It also mediates different cellular functions and processes such as proliferation, senescence, apoptosis, autophagy, and inflammatory responses in various cell types. In mammals, there are two isoenzymes, ARG-1 and ARG-2; they are functionally similar, but their coding genes, tissue distribution, subcellular localization, and molecular regulation are distinct.

View Article and Find Full Text PDF

Background: Diet significantly impacts the onset and progression of inflammatory bowel disease (IBD), and diet offers unique opportunities for treatment and preventative purposes. However, despite growing interest, no diet has been conclusively associated with improved long-term clinical and endoscopic outcomes in IBD, and evidence-based dietary guidelines for IBD remain scarce. This narrative review critically examines dietary assessment methods tailored to the unique needs of IBD, highlighting opportunities for precision and inclusivity.

View Article and Find Full Text PDF

To assess nutritional intake of patients with inflammatory bowel disease (IBD), a disease-specific food frequency questionnaire (FFQ) was developed: the Groningen IBD Nutritional Questionnaire (GINQ-FFQ). Aim of this study was to assess the relative validity of the GINQ-FFQ. Between 2019 and 2022, participants of the 1000IBD cohort were included and filled out a 3-day food diary and the GINQ-FFQ.

View Article and Find Full Text PDF

Background/objectives: Ulcerative colitis (UC) is a chronic and easily recurrent inflammatory bowel disease. The gut microbiota and plasma metabolites play pivotal roles in the development and progression of UC. Therefore, therapeutic strategies targeting the intestinal flora or plasma metabolites offer promising avenues for the treatment of UC.

View Article and Find Full Text PDF

Background/objectives: Janus kinase inhibitors open new horizons for small-molecule drugs in treating inflammatory bowel disease, with ritlecitinib demonstrating significant efficacy in clinical trials for ulcerative colitis and Crohn's disease. Ritlecitinib, a second-generation JAK3 inhibitor, is a novel therapeutic agent for alopecia areata and other autoimmune conditions.

Methods: A new stability-indicating UHPLC-DAD-MS/MS method was developed, validated, and applied for a forced degradation study of ritlecitinib under ICH guidelines.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!